The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine : A post-hoc analysis of pooled real-world data
Copyright © 2023. Published by Elsevier B.V..
INTRODUCTION: Intravenous ketamine (KET-IV) and intranasal esketamine (ESK-NS) are effective in the acute treatment of Treatment-Resistant Depression (TRD). Studies comparing KET-IV and ESK-NS concerning their action, safety, and tolerability are currently lacking.
MATERIALS AND METHODS: We combined patients' data from two unipolar TRD cohorts that received KET-IV (n = 171) at the Canadian Rapid Treatment Center of Excellence in Toronto, Canada, or ESK-NS (n = 140) at several TRD clinics in Italy. The Quick Inventory for Depression Symptomatology-Self-Report-16/QIDS-SR16 in the KET-IV group and Montgomery-Åsberg Depression Rating Scale/MADRS in the ESK-NS group measured depressive symptoms at baseline (T0) and after the acute treatment phase (T1) (i.e., four infusions of KET-IV and eight administrations of ESK-NS). As different scales were used, the primary outcome was to compare the improvement in depression severity in the two cohorts by measuring effect sizes, response and remission rates. Finally, we compare side effects and discontinuation rates.
RESULTS: At T1, KET-IV and ESK-NS significantly reduced depressive symptoms (respectively: QIDS-SR16 mean reduction = 5.65, p < 0.001; MADRS mean reduction = 11.41, p = 0.025). KET-IV showed larger effect sizes compared to ESK-NS (1.666 vs. 1.244). KET-IV had higher response rates (36 % vs. 25 %; p = 0.042) but not superior remission rates (13 % vs. 12 %; p = 0.845) than ESK-NS at T1. Despite more reported side effects, KET-IV did not cause more discontinuations for adverse events (4.6 % vs. 2.12 %; p = 0.228) than ESK-NS.
CONCLUSION: KET-IV showed a higher short-term antidepressant effect, whereas ESK-NS exhibited lower side effects. Both were generally well tolerated. Future head-to-head studies should consider the long-term efficacy of these treatments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:348 |
|---|---|
| Enthalten in: |
Journal of affective disorders - 348(2024) vom: 01. Jan., Seite 314-322 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
d'Andrea, Giacomo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
50LFG02TXD |
|---|
| Anmerkungen: |
Date Completed 22.01.2024 Date Revised 22.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jad.2023.12.038 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366365045 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366365045 | ||
| 003 | DE-627 | ||
| 005 | 20240122232017.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jad.2023.12.038 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1267.xml |
| 035 | |a (DE-627)NLM366365045 | ||
| 035 | |a (NLM)38145840 | ||
| 035 | |a (PII)S0165-0327(23)01506-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a d'Andrea, Giacomo |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine |b A post-hoc analysis of pooled real-world data |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.01.2024 | ||
| 500 | |a Date Revised 22.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a INTRODUCTION: Intravenous ketamine (KET-IV) and intranasal esketamine (ESK-NS) are effective in the acute treatment of Treatment-Resistant Depression (TRD). Studies comparing KET-IV and ESK-NS concerning their action, safety, and tolerability are currently lacking | ||
| 520 | |a MATERIALS AND METHODS: We combined patients' data from two unipolar TRD cohorts that received KET-IV (n = 171) at the Canadian Rapid Treatment Center of Excellence in Toronto, Canada, or ESK-NS (n = 140) at several TRD clinics in Italy. The Quick Inventory for Depression Symptomatology-Self-Report-16/QIDS-SR16 in the KET-IV group and Montgomery-Åsberg Depression Rating Scale/MADRS in the ESK-NS group measured depressive symptoms at baseline (T0) and after the acute treatment phase (T1) (i.e., four infusions of KET-IV and eight administrations of ESK-NS). As different scales were used, the primary outcome was to compare the improvement in depression severity in the two cohorts by measuring effect sizes, response and remission rates. Finally, we compare side effects and discontinuation rates | ||
| 520 | |a RESULTS: At T1, KET-IV and ESK-NS significantly reduced depressive symptoms (respectively: QIDS-SR16 mean reduction = 5.65, p < 0.001; MADRS mean reduction = 11.41, p = 0.025). KET-IV showed larger effect sizes compared to ESK-NS (1.666 vs. 1.244). KET-IV had higher response rates (36 % vs. 25 %; p = 0.042) but not superior remission rates (13 % vs. 12 %; p = 0.845) than ESK-NS at T1. Despite more reported side effects, KET-IV did not cause more discontinuations for adverse events (4.6 % vs. 2.12 %; p = 0.228) than ESK-NS | ||
| 520 | |a CONCLUSION: KET-IV showed a higher short-term antidepressant effect, whereas ESK-NS exhibited lower side effects. Both were generally well tolerated. Future head-to-head studies should consider the long-term efficacy of these treatments | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comparative study | |
| 650 | 4 | |a Intranasal esketamine | |
| 650 | 4 | |a Intravenous ketamine | |
| 650 | 4 | |a TRD | |
| 650 | 4 | |a Treatment-resistant depression | |
| 650 | 7 | |a Esketamine |2 NLM | |
| 650 | 7 | |a 50LFG02TXD |2 NLM | |
| 650 | 7 | |a Ketamine |2 NLM | |
| 650 | 7 | |a 690G0D6V8H |2 NLM | |
| 650 | 7 | |a Antidepressive Agents |2 NLM | |
| 700 | 1 | |a Pettorruso, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Di Lorenzo, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Rhee, Taeho Greg |e verfasserin |4 aut | |
| 700 | 1 | |a Chiappini, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Carullo, Rosalba |e verfasserin |4 aut | |
| 700 | 1 | |a Barlati, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Zanardi, Raffaella |e verfasserin |4 aut | |
| 700 | 1 | |a Rosso, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Di Nicola, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Andriola, Ileana |e verfasserin |4 aut | |
| 700 | 1 | |a Marcatili, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Clerici, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Dell'Osso, Bernardo Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Sensi, Stefano L |e verfasserin |4 aut | |
| 700 | 1 | |a Mansur, Rodrigo B |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenblat, Joshua D |e verfasserin |4 aut | |
| 700 | 1 | |a Martinotti, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a McIntyre, Roger S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of affective disorders |d 1989 |g 348(2024) vom: 01. Jan., Seite 314-322 |w (DE-627)NLM000465615 |x 1573-2517 |7 nnns |
| 773 | 1 | 8 | |g volume:348 |g year:2024 |g day:01 |g month:01 |g pages:314-322 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jad.2023.12.038 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 348 |j 2024 |b 01 |c 01 |h 314-322 | ||